BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23123214)

  • 1. The response to interferon is influenced by hepatitis B virus genotype in vitro and in vivo.
    Zhang Y; Wu Y; Ye S; Wang T; Zhao R; Chen F; Abe K; Jin X
    Virus Res; 2013 Jan; 171(1):65-70. PubMed ID: 23123214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
    Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro resistance to interferon-alpha of hepatitis B virus with basic core promoter double mutation.
    Wang Y; Wei L; Jiang D; Cong X; Fei R; Chen H; Xiao J; Wang Y
    Antiviral Res; 2007 Aug; 75(2):139-45. PubMed ID: 17397939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between HBV genotypes and anti-viral therapeutic efficacy of interferon-alpha.
    Ma JC; Wang LW; Li XJ; Liao YF; Hu XY; Gong ZJ
    Hepatobiliary Pancreat Dis Int; 2007 Apr; 6(2):166-71. PubMed ID: 17374576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus sensitivity to interferon-α in hepatocytes is more associated with cellular interferon response than with viral genotype.
    Shen F; Li Y; Wang Y; Sozzi V; Revill PA; Liu J; Gao L; Yang G; Lu M; Sutter K; Dittmer U; Chen J; Yuan Z
    Hepatology; 2018 Apr; 67(4):1237-1252. PubMed ID: 29059468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.
    Klumpp K; Shimada T; Allweiss L; Volz T; Lütgehetmann M; Hartman G; Flores OA; Lam AM; Dandri M
    Gastroenterology; 2018 Feb; 154(3):652-662.e8. PubMed ID: 29079518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/HeN mice.
    Peng XH; Ren XN; Chen LX; Shi BS; Xu CH; Fang Z; Liu X; Chen JL; Zhang XN; Hu YW; Zhou XH
    World J Gastroenterol; 2015 Mar; 21(12):3527-36. PubMed ID: 25834317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens.
    Sugiyama M; Tanaka Y; Kato T; Orito E; Ito K; Acharya SK; Gish RG; Kramvis A; Shimada T; Izumi N; Kaito M; Miyakawa Y; Mizokami M
    Hepatology; 2006 Oct; 44(4):915-24. PubMed ID: 17006908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The relationship between HBV genotypes and the efficacy of antiviral therapies in hepatitis B e antigen- positive patients].
    Zou HB; Zhu LM; Zhao GM; Liang SR; Li J; Lu CZ; Li H
    Zhonghua Gan Zang Bing Za Zhi; 2007 Jun; 15(6):425-7. PubMed ID: 17594806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance.
    Hou J; Schilling R; Janssen HL; Hansen BE; Heijtink R; Sablon E; Williams R; Lau GK; Schalm SW; Naoumov NV
    J Med Virol; 2007 Aug; 79(8):1055-63. PubMed ID: 17596838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Based on the low-density cDNA Macroarray for screening of antiviral proteins of IFNa tissues].
    Guan SH; Yang K; Wang J; Cheng ZL; Pan Y; Wu YY; Yang DL
    Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):774-8. PubMed ID: 22409852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy.
    Hung CH; Chen CH; Lu SN; Wang JH; Hu TH; Huang CM; Tsai MC; Lee CM
    Antiviral Res; 2012 Jan; 93(1):55-63. PubMed ID: 22061616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral potential of interferon-omega on hepatitis B virus replication in human hepatoma cells.
    Hagelstein J; Kist A; Stremmel W; Galle PR
    Arzneimittelforschung; 1998 Mar; 48(3):343-7. PubMed ID: 9553691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-stimulated gene of 20 kDa protein (ISG20) degrades RNA of hepatitis B virus to impede the replication of HBV in vitro and in vivo.
    Leong CR; Funami K; Oshiumi H; Mengao D; Takaki H; Matsumoto M; Aly HH; Watashi K; Chayama K; Seya T
    Oncotarget; 2016 Oct; 7(42):68179-68193. PubMed ID: 27626689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to antiviral treatment in patients infected with hepatitis B virus genotypes E-H.
    Erhardt A; Göbel T; Ludwig A; Lau GK; Marcellin P; van Bömmel F; Heinzel-Pleines U; Adams O; Häussinger D
    J Med Virol; 2009 Oct; 81(10):1716-20. PubMed ID: 19697400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro resistance to interferon of hepatitis B virus with precore mutation.
    Wang Y; Wei L; Jiang D; Cong X; Fei R; Xiao J; Wang Y
    World J Gastroenterol; 2005 Feb; 11(5):649-55. PubMed ID: 15655815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific expression of human interferon-gamma controls hepatitis B virus replication in vitro in secreting hepatitis B surface antigen hepatocytes.
    Kan Q; Li D; Yu Z
    J Virol Methods; 2012 Mar; 180(1-2):84-90. PubMed ID: 22240074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of long-term interferon therapy in chronic hepatitis B patients with HBV genotype C.
    Sakai T; Shiraki K; Inoue H; Okano H; Deguchi M; Sugimoto K; Ohmori S; Murata K; Nakano T
    Int J Mol Med; 2002 Aug; 10(2):201-4. PubMed ID: 12119559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of interferon-γ and tumor necrosis factor-α on hepatitis B virus following lamivudine treatment.
    Shi H; Lu L; Zhang NP; Zhang SC; Shen XZ
    World J Gastroenterol; 2012 Jul; 18(27):3617-22. PubMed ID: 22826629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-terminal and C-terminal cytosine deaminase domain of APOBEC3G inhibit hepatitis B virus replication.
    Lei YC; Tian YJ; Ding HH; Wang BJ; Yang Y; Hao YH; Zhao XP; Lu MJ; Gong FL; Yang DL
    World J Gastroenterol; 2006 Dec; 12(46):7488-96. PubMed ID: 17167839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.